No Night Shift Pathology services for Physical Biopsy Analysis – Urgent Need for Digital Biopsies

No Night Shift Pathology services for Physical Biopsy Analysis– Urgent Need for Digital Biopsies

Further to my previous posts regarding an Adelaide cardiothoracic surgeon removing part of a man’s lung based upon a biopsy sample that had been allegedly incorrectly analysed because the sample became cross-contaminated. And how a digital biopsy would have avoided this error.

More issues have arisen.

In fact, an Adelaide Pathology laboratory has closed its night shifts to prevent the occurrence of tired pathologists from misdiagnosing biopsy samples.

In addition, the Inquest into the death of Dennis Jackson in Adelaide heard evidence that a pathologist was prone to making mistakes late at night.

Questions

(1) Does a pathologist wearing the same protective clothing for each analysis contribute to the risk of contamination of the tissue samples?

(2) Is it acceptable for a laboratory to simply wipe down forceps used while analysing biopsy samples? I contend that at a minimum forceps should be burned with a Bunsen burner before use on another sample.

Following on, there now appears to be three issues:

(1) Contamination of biopsy samples;

(2) Pathologists misdiagnosing biopsy samples because they are tired; and

(3) Negligent pathologists and poor laboratory work practises.

The question arises how many cancerous samples have been misdiagnosed as non- cancerous.

Moreover, should patients who have previously had a biopsy sample analysed between 10 pm to 8 am, have another physical biopsy.

In conclusion,

The removal of late-night pathology services may reducethe occurrence of misdiagnosis but it will not eliminate the misdiagnosing ofbiopsy samples.

Digital biopsies have many compelling advantages over the current physical biopsies.

Optiscan’s InVivage is the undisputed world gold standard for digital biopsies.

Artificial Intelligence will significantly enhance InVivage.

After the pending FDA approval of InVivage; CE and TGA approval should be fast tracked to enable the equipment’s use in Europe and Australia.

In the interim, after FDA approval, Australian residents should consider obtaining cancer treatment in the USA at hospitals using InVivage.

Significant InVivage sales will occur in the USA immediately following the FDA approval.

Optiscan shares at 10.5 cents is a significant under evaluation of a stock that should be trading in the 80 cents to $1.30 range. Leaving the company exposed to a takeover. Be in no doubt significant medical equipment manufacturers are closely monitoring Optiscan. The only question in their minds is when will the technology go nuclear.

2023 is Optiscan’s year to shine.

This post refers to and should be read in conjunction with:

https://hotcopper.com.au/threads/physical-biopsy-failures-%E2%80%93-cross-contamination-of-sample-%E2%80%93-is-there-an-alternative.7221174/

https://hotcopper.com.au/threads/digital-biopsy-a-safe-guard-to-prevent-mistakes-and-more.7221448/